The Every Company secures US$55M to expand precision-fermented egg protein production
The funding will support the expansion of manufacturing capabilities and operational growth.
USA – The Every Company, a biotechnology leader pioneering precision fermentation for highly functional proteins, has successfully raised US$55 million in a Series D funding round to dramatically expand the production and commercialization of its precision-fermented egg proteins.
The round was led by McWin Capital Partners through its Food Tech Fund, with participation from notable investors including Main Sequence, Bloom8, TO.VC, Minerva Foods, Grosvenor Food & Ag, New Agrarian, and SOSV.
This infusion of capital will enable The Every Company to significantly scale its manufacturing capacity and achieve profitability, further penetrating the growing alternative protein market.
The company specializes in producing animal-free egg proteins through precision fermentation, replicating the functional properties of traditional eggs without animal ingredients.
The Every Company’s products are already available across retail, foodservice, and e-commerce channels, with a recent rollout in Walmart stores nationwide serving as a major proof point and boost to the industry.
These products offer a promising alternative amid ongoing pressures on the traditional egg supply chain, such as avian flu outbreaks, rising feed costs, and fluctuating market conditions.
The funding will support the expansion of manufacturing capabilities and operational growth as The Every Company aims to capture a larger share of the US$270 billion global egg market, with a particular focus on high-volume applications such as baking and food manufacturing.
Their precision-fermented egg proteins are shelf-stable powdered ingredients that can be stored for up to 18 months without refrigeration, delivering logistical and distribution efficiencies for food producers.
CEO and co-founder Arturo Elizondo highlighted that this capital injection will help the company fulfill its mission of making functional, animal-free egg proteins accessible nationwide, promoting sustainability and food security.
The Every Company’s approach also represents a shift in the alternative protein industry by demonstrating that scaling production can pave the way for broader regulatory acceptance, potentially accelerating the adoption of innovation in food technology.
This funding milestone underscores investor confidence in The Every Company as a leading innovator well positioned to challenge traditional eggs while meeting consumer demand for sustainable, ethical, and healthy food options.
Sign up to HERE receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.
